STAT News

JUNE 26, 2025

A committee that advises the Centers for Disease Control and Prevention on vaccines voted Thursday to recommend the use of a new monoclonal antibody against RSV in babies, Merck’s Enflonsia. 

Vaccine 127

Vaccine Vaccination Antibody Production 127

Scienmag

JUNE 23, 2025

The imaging agent’s structural design—an antibody fragment labeled with gallium-68—embodies a strategic convergence of immunology and nuclear medicine.

Medicine 81

Medicine Antibody Research Engineer 81

Bio Pharma Dive

JULY 7, 2025

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less frequent dosing.

Antibody 141

Antibody Drugs 141

XTalks

JANUARY 21, 2025

The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. Datroway leverages DXd technology to precisely target cancer cells.

Antibody 105

Antibody FDA Approval HR Trials 105

Scienmag

JULY 18, 2025

Applying PathoPlex to this system, the investigators deployed an antibody panel targeting 34 markers, including those indicative of cell identity, subcellular compartments, and critical signaling pathways, all captured at an astonishing spatial resolution of 80 nanometers per pixel.

Antibody 90

Antibody In-Vivo In-Vitro Research 90

Scienmag

JUNE 18, 2025

By harnessing a synergistic combination of two powerful adjuvants within a single vaccine dose, this method elicits a dramatically enhanced immune response, notably broadening the diversity and potency of antibodies produced.

Vaccine 90

Vaccine Vaccination Immune Response Antibody 90

Pharma Times

JULY 10, 2025

Comparable local and systemic reactions were reported across all treatment groups, and HA-specific antibody responses remained consistent across all four influenza strains. Robust NP-specific humoral and cell-mediated immune responses were observed in all participants given OVX836, whether alone or with Fluarix Tetra.

Vaccine 81

Vaccine Vaccination Immune Response Trials 81

Scienmag

JUNE 7, 2025

This nationwide experience involved meticulous data collection from multiple tertiary referral centers, encompassing a comprehensive array of pediatric patients systematically treated with a spectrum of biologic agents, including monoclonal antibodies targeting IL-5, IL-13, and other pivotal cytokines implicated in EoE pathogenesis.

Medicine 78

Medicine Immune Response Research Nurses 78

Scienmag

JUNE 19, 2025

Theresa Hunter and her team have pioneered a transformative method whereby lipid nanoparticles, engineered with a novel ionizable lipid designated L829, are conjugated with antibodies targeting CD5—a protein prominently expressed on T cells.

In-Vivo 52

In-Vivo Engineer Manufacturing DNA 52

The Pharma Data

JUNE 25, 2025

FDA Orphan Drug Designation for Antibody-Mediated Rejection in Solid Organ Transplantation The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to riliprubart , an investigational immunology therapy developed by Sanofi, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.

Antibody 40

Antibody Drugs FDA Approval Clinical Trials 40

XTalks

MAY 13, 2025

One compelling example he discusses involves a bispecific antibody engineered to simultaneously block PD-1 an immune checkpoint receptor expressed on T cells and VEGF, a key angiogenic factor that drives blood vessel formation throughout the body.

Antibody 52

Antibody Clinical Trials Clinical Trials Immune Response 52

Worldwide Clinical Trials

OCTOBER 14, 2024

For instance, drugs like belimumab, a monoclonal antibody, have shown promise in treating systemic lupus erythematosus and lupus nephritis by reducing the overactive immune response. Similarly, anabolic agents like teriparatide are used to stop bone loss and stimulate new bone growth in osteoporosis.

Research 130

Research Clinical Trials Clinical Trials Immune Response 130

Drug Discovery World podcast

JULY 17, 2025

They are called: “ Decoding diseases: The AI renaissance in clinical trials ” and “ Advancing antibody discovery with AI ”. This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023.

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

pharmaphorum

OCTOBER 30, 2024

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for drugs in its class.Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the (..)

Antibody 111

Antibody Drugs 111

Bio Pharma Dive

JUNE 4, 2025

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.

Drugs 195

Drugs Antibody Development 195

The Pharma Data

JULY 2, 2025

ARGX-119 is a first-in-class agonist antibody that targets muscle-specific kinase (MuSK), a protein critical to the function of neuromuscular junctions. Detailed data from the trial will be shared at an upcoming medical conference. Peter Ulrichts, Ph.D.,

Trials 40

Trials Clinical Trials Clinical Trials Protein 40

XTalks

NOVEMBER 21, 2024

The test, the first of its kind approved for over-the-counter (OTC) use in the US, detects antibodies for Treponema pallidum , the bacterium responsible for syphilis. NOWDiagnostics’ First To Know Syphilis Test circumvents these barriers with a convenient, in-home solution offering results in just 15 minutes. percent for positive cases.

Bacterium 104

Bacterium Antibody Manufacturing Pharmacy 104

Scienmag

JUNE 29, 2025

Most notably, molecular signatures indicative of antibody-mediated rejection emerged as early as Day 10 post-transplant, intensifying up to Day 33. These findings align with prior clinical observations, reinforcing the concept of a rapid yet evolving immune rejection timeline.

Bioinformatics 59

Bioinformatics Genetics Immune Response Gene 59

Bio Pharma Dive

JUNE 4, 2025

Doctors also wrestled with how best to use new bispecific antibodies, and expressed concern about looming cuts to science funding. Breast cancer study results impressed at this year’s meeting, but raised new questions.

Doctor 180

Doctor Doctors Antibody Drugs 180

XTalks

APRIL 15, 2025

This includes potential label expansions for antibody-drug conjugate Blenrep (belantamab mafodotin-blmf) and asthma treatment Nucala (mepolizumab). The company is also planning the launch of its IL-5 targeting antibody depemokimab as an add-on maintenance asthma treatment.

FDA Approval 66

FDA Approval Bacteria DNA Bacterium 66

XTalks

MARCH 10, 2025

Omalizumab is an anti-IgE antibody that works by blocking the effects of IgE, a key driver in many allergic reactions. Originally approved by the FDA over two decades ago for the treatment of moderate to severe persistent asthma, Xolair recently also gained approval for managing food allergies.

Allergies 66

Allergies FDA Approval Antibody Trials 66

XTalks

JULY 4, 2025

The FDA has granted accelerated approval to Regeneron’s BCMA-targeting bispecific antibody linvoseltamab-gcpt, marketed as Lynozyfic, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.

FDA Approval 59

FDA Approval Antibody Trials Clinical Development 59

The Pharma Data

JUNE 22, 2025

a subsidiary of the Roche Group, NXT007 represents a next-generation therapeutic approach that builds upon the foundation established by Hemlibra® (emicizumab), Roche’s first-in-class bispecific antibody approved for prophylactic treatment of hemophilia A. Engineered by Chugai Pharmaceutical Co.,

Antibody 40

Antibody Clinical Trials Clinical Trials Trials 40

The Pharma Data

JUNE 24, 2025

This collaborative arrangement allows Bio-Techne to distribute USP’s reference standards for monoclonal antibodies (mAbs) and recombinant adeno-associated viruses (AAVs) alongside its advanced analytical platforms—most notably the MauriceFlex™ system.

Gene Therapy 40

Gene Therapy Gene Development Manufacturing 40

Worldwide Clinical Trials

OCTOBER 14, 2024

For instance, drugs like belimumab, a monoclonal antibody, have shown promise in treating systemic lupus erythematosus and lupus nephritis by reducing the overactive immune response. Similarly, anabolic agents like teriparatide are used to stop bone loss and stimulate new bone growth in osteoporosis.

Research 147

Research Clinical Trials Clinical Trials Immune Response 147

The Pharma Data

JUNE 18, 2025

A Next-Generation Antibody-Drug Conjugate Targeting B7-H3 Ifinatamab deruxtecan is a potential first-in-class antibody-drug conjugate (ADC) specifically engineered to target B7-H3 , a surface protein overexpressed in many solid tumors, including prostate cancer. Source link

Trials 40

Trials Antibody Clinical Trials Clinical Trials 40

XTalks

JUNE 11, 2025

In a recent webinar , Indraneel Sanyal, Senior Director of Process Development at Aragen, detailed how the company adapted its monoclonal antibody (mAb) purification platform by transitioning from traditional resin-based Protein A chromatography to a membrane-based format.

Protein 92

Protein Manufacturing Antibody Production 92

pharmaphorum

OCTOBER 22, 2024

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.The Japanese drugmaker said that interim results from the 530-patient VISIONARY study showed that sibeprenlimab achieved a statistically significant and clinically (..)

Drugs 119

Drugs Protein Antibody 119

XTalks

JANUARY 29, 2025

Related: Eli Lillys Kisunla (donanemab) Gets Full FDA Approval After Initial Rejection, Gears Up to Take on Leqembi Leqembi was first approved in 2023 as a monoclonal antibody targeting amyloid-beta protofibrils and plaques proteins that cause brain cell damage and cognitive decline in Alzheimers disease.

FDA Approval 66

FDA Approval Antibody Sales Protein 66

Scienmag

JUNE 10, 2025

Small molecule inhibitors and monoclonal antibodies targeting these enzymes are actively being explored. On a molecular level, critical enzymes such as hexokinase 2 (HK2), glutaminase (GLS), and fatty acid synthase (FASN) have surfaced as central regulatory nodes in breast cancer’s metabolic network.

Gene 75

Gene Medicine Hormones Research 75

Pharmaceutical Technology

MAY 23, 2025

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

FDA Approval 130

FDA Approval Antibody Drugs 130

Scienmag

JUNE 17, 2025

The inherent biological complexity of human milk, rich in bioactive components such as antibodies, growth factors, and beneficial microbiota, plays a crucial role in mitigating these risks and supporting optimal growth trajectories.

Research 69

Research Containment Development Protein 69

Scienmag

JULY 5, 2025

In preclinical melanoma models, inosine administration alongside anti-CTLA4 and anti-PD1 antibodies significantly curbs tumor growth, highlighting the potential of metabolic adjuvants to enhance immunotherapeutic outcomes.

Immune Response 86

Immune Response Engineer Regulation Production 86

Pharma Times

JUNE 30, 2025

Analyses included 60,000 antibody assays and 450 PCR tests, plus detailed genotypic and phenotypic reviews carried out at the company’s Canary Wharf laboratory. Participants were given either CD388 or a placebo, then monitored over 24 weeks through regular check-ups while living outside the clinic.

Genotype 72

Genotype Clinical Research Insulin Trials 72

XTalks

MAY 2, 2025

Among patients with advanced NSCLC with TKD HER2 mutations who had previously received platinum-based chemotherapy and HER2-targeted antibody-drug conjugates (ADCs), zongertinib achieved a 48% ORR and a 97% DCR. Zongertinibs efficacy extended to various patient subgroups. Among patients with non-TKD HER2 mutations, the ORR was 30%.

FDA Approval 98

FDA Approval Trials Drugs Clinical Trials 98

The Pharma Data

JUNE 25, 2025

However, the emergence of amyloid-targeting therapies , such as monoclonal antibodies that clear amyloid from the brain, has given new purpose to diagnostic imaging tools. At the time, its use was primarily restricted to supporting the diagnostic process.

FDA Approval 52

FDA Approval Protein Development Antibody 52

Fierce Pharma

JULY 2, 2025

After a delay, Regeneron’s BCMA-directed bispecific antibody Lynozyfic has won an FDA approval with a more convenient dosing regimen than competitor multiple myeloma offerings from Johnson & Johnson and Pfizer.

FDA Approval 82

FDA Approval Antibody 82